Technical note: Dosimetric study for the new BEBIG 60Co HDR source used in brachytherapy in water and different media using Monte Carlo N-Particle eXtended code.

Technical note: Dosimetric study for the new BEBIG 60Co HDR source used in brachytherapy in water and different media using Monte Carlo N-Particle eXtended code. Appl Radiat Isot. 2020 May;159:109087 Authors: Elboukhari S, Yamni K, Ouabi H, Bouassa T, Ait Mlouk L Abstract This work aims to study the dosimetrc parameters of the new 60Co-source model Co0.A86 used in high dose rate brachytherapy and manufactured by BEBIG (Eckert &Ziegler BEBIG GmbH, Germany). The radial dose function, 2D along&away dose rates and the dose rate constant were investigated in a water phantom. Accordingly, we use the recommendations from the AAPM and ESTRO on dose calculation for high-energy (average energy higher than 50 keV) photon-emitting brachytherapy sources cited in the HEBD working group report. Furthermore, we compared the obtained results with the quoted values in the previous studies. The value of air-kerma strength calculated in this work was 3.030 ± 0.002 UBq-1. Moreover, the radial dose function and 2D along&away dose rates are evaluated in different tissues and compared with the results obtained in the water and we found a notable difference. To reach the goal we have used MCNPX code for simulation. PMID: 32250762 [PubMed - as supplied by publisher]
Source: Applied Radiation and Isotopes - Category: Radiology Authors: Tags: Appl Radiat Isot Source Type: research

Related Links:

Radiation treatment (RT) is an effective option for men with localized prostate cancer (PCa).[1] However, local recurrences (LR) remain common in patients treated with external beam radiotherapy (EBRT) alone.[2] Dose-escalated RT to the whole gland (WG) has demonstrated increased locoregional and biochemical control in localized PCa.[3-5] A meta-analysis concluded that each 1-Gray (Gy) increased in dose delivered reduces 1.8% the risk of biochemical failure.[6] Nevertheless, concerns have been raised with regards to increased toxicity and subsequently worsening the quality of life (QoL) of patients treated with dose escalation.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Conditions:   Metastatic Malignant Female Reproductive System Neoplasm;   Platinum-Resistant Malignant Female Reproductive System Neoplasm;   Recurrent Malignant Female Reproductive System Neoplasm;   Refractory Malignant Female Reproductive System Neoplasm Interventions:   Biological: Durvalumab;   Radiation: Internal Radiation Therapy;   Biological: Tremelimumab Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
As aging is the most significant risk factor for cancer development, long-term prostate cancer (PCa) survivors have an evident risk of developing subsequent primary cancers (SPCs). Radiotherapy itself is an ad...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
CONCLUSION: At the current level of disease in the United States, all three models have sustained major system stress in continuing reduced operation. However, the small clinic model may not perform if either the current level of infections is maintained for long or staff becomes unavailable due to health issues. With abundance, and diversity of innovative resources, medium and large clinic models can sustain further for physics-related radiotherapy services. PMID: 32432389 [PubMed - as supplied by publisher]
Source: Journal of Applied Clinical Medical Physics - Category: Physics Authors: Tags: J Appl Clin Med Phys Source Type: research
In the last years, Selective Internal Radiation Therapy (SIRT), using biocompatible Yttrium-90 (90Y) labeled microspheres have emerged for the treatment of malignant hepatic tumors. Unfortunately, a significan...
Source: BMC Medical Imaging - Category: Radiology Authors: Tags: Case report Source Type: research
CONCLUSION: There are no increased hazards for choroidal melanoma-related mortality after brachytherapy with decreasing doses between 108.6 and 73.0 Gy, or with decreasing dose rates between 2.8 and 0.5 Gy/hour. PMID: 32430342 [PubMed - as supplied by publisher]
Source: The British Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Br J Ophthalmol Source Type: research
Esophageal cancer is characterized by its propension to local evolution, which conditions prognosis and quality of life. Brachytherapy may be a therapeutic option for all stages of esophageal cancer.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: DW-MRI is a promising method for monitoring patients with choroidal melanoma; reduction in the mean ADC values between pre-treatment MRI and the first post-treatment MRI may be related to the lack of response to brachytherapy and increased risk of disease progression.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractThis manuscript introduces a novel open-ended, multichannel intracavitary-interstitial hybrid applicator for gynecological high-dose-rate brachytherapy. A prototype was three-dimensionally (3D) printed using polylactic acid. The device was 25 mm in diameter and 150 mm in length, with eight evenly spaced peripheral channels around a central tandem channel, each 2.7 mm in diameter and with 2 mm source-to-cylinder-surface-distance. In contrast to conventional multichannel applicators, the new hybrid applicator was designed with open distal ends. Interstitial needles utilized in peripheral channels provided a closed en...
Source: Radiological Physics and Technology - Category: Physics Source Type: research
The use of Yttrium-90 microspheres in liver malignancies is known by two names: selective internal radiation therapy (SIRT) and transarterial radioembolization (TARE). Interestingly, the two names reflect two representations of the therapy, and might be a reason why the role of SIRT in the field of hepatocellular carcinoma (HCC) treatment is still not clear in the mind of many clinicians. While some guidelines (i.e. EASL's) do not recommend its use, others (i.e. ESMO's) do recognize some space in the therapeutic armamentarium.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Editorial Source Type: research
More News: Brachytherapy | Germany Health | Radiology | Study